1.
Pediatr Infect Dis J
; 42(2): 119-121, 2023 02 01.
Article
in English
| MEDLINE | ID: covidwho-2190920
ABSTRACT
We describe the clinical characteristics and outcomes of 16 children and young adults with severe acute COVID-19 who were treated with tocilizumab. Patients who were discharged by day 28 were more likely to be treated with tocilizumab earlier in their COVID-19 illness and had lower ferritin and interleukin-6 levels compared with those who were not discharged by day 28.